Improving the diagnosis, management, and outcomes of children with pneumonia: where are the gaps?
- 1Queensland Children’s Respiratory Centre, Queensland Children’s Medical Research Institute, Queensland University of Technology, Brisbane, QLD, Australia
- 2Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia
- 3Department of Pediatrics, Kuching Hospital, Sarawak, Malaysia
- 4Institute of Health and Community Medicine, Universiti Malaysia Sarawak, Kota Samarahan, Malaysia
- 5Queensland Children’s Medical Research Institute, The University of Queensland, Brisbane, QLD, Australia
- 6Queensland Paediatric Infectious Diseases Laboratory, Royal Children’s Hospital, Brisbane, QLD, Australia
Pneumonia is the greatest contributor to childhood mortality and morbidity in resource-poor regions, while in high-income countries it is one of the most common reasons for clinic attendance and hospitalization in this age group. Furthermore, pneumonia in children increases the risk of developing chronic pulmonary disorders in later adult life. While substantial advances in managing childhood pneumonia have been made, many issues remain, some of which are highlighted in this perspective. Multiple studies are required as many factors that influence outcomes, such as etiology, patient characteristics, and prevention strategies can vary between and within countries and regions. Also, outside of vaccine studies, most randomized controlled trials (RCTs) on pneumonia have been based in resource-poor countries where the primary aim is usually prevention of mortality. Few RCTs have focused on medium to long-term outcomes or prevention. We propose different tiers of primary outcomes, where in resource-rich countries medium to long-term sequelae should also be included and not just the length of hospitalization and readmission rates.
Why Childhood Pneumonia is Important
Childhood pneumonia is of worldwide importance for several reasons. Firstly, while many illnesses receive relatively more attention, pneumonia remains the most important cause of mortality and morbidity in young children globally (1, 2). Secondly, deaths from pneumonia are largely preventable in this age group. Thirdly, pneumonia, especially when recurrent, is linked to future chronic lung disease (3). Thus, interventions that reduce pneumonia and acute lower respiratory infections (ALRIs) have both short and long-term benefits. This perspective is not a comprehensive review of childhood pneumonia and its management. Instead, it aims to highlight the many gaps in our knowledge so as to stimulate and improve clinical research in pneumonia that will lead subsequently to improved clinical care.
Global Pneumonia Burden
Pneumonia is the largest (18%) single cause of death in children aged <5-years (1). Global estimates of the annual incidence of pneumonia in children aged <5-years range from 120 to 160 million episodes, with more than 99% occurring in resource-limited countries (1). While there are substantial inter-country and inter-continental differences in the annual incidence of pneumonia [0.33 episodes per child-year in Africa, 0.05 in developed countries (1, 2)], there is also intra-continental (4) and wide intra-country variability (1, 5). For example, in South America, the percentage of childhood deaths under the age of 5-years attributable to pneumonia is much lower in Chile and Uruguay (5–10%) than in Bolivia, Peru, and Guyana (15–20%) (4). Also, in contrast to the rest of affluent Australia, ALRIs (encompassing pneumonia) are the commonest cause of preventable deaths in infants, emergency medical retrievals from remote communities, and hospitalizations among Indigenous children aged <5-years (6, 7). Hospitalized-pneumonia incidence of infants in the Northern Territory of Australia (the region with the highest proportion of Indigenous people) is 0.43 per child-year (8). Similarly, Indigenous children in New Zealand and the United States (US) also bear a substantially disproportionate burden of disease (9, 10). Nevertheless, while there is little doubt that socio-economic issues are important, pneumonia remains one of the most common causes of hospitalization in children, even in resource-rich countries where before the widespread adoption of pneumococcal conjugate vaccines (PCVs) an estimated 1.5 million children aged <5-years were admitted annually.
The Knowledge Gaps
Epidemiological estimates of pneumonia depend upon the accuracy of data collection, which is problematic because of: (a) absence of a diagnostic gold standard, (b) lack of resources to collect data systematically (especially in resource-poor countries), and (c) considerable intra-country variation making extrapolation of data subject to biases, especially when universal health systems are sub-optimal and people seek treatment in the private sector (where data capture is more difficult).
Acute lower respiratory infections are caused by several respiratory viral and bacterial pathogens, often in combination with one another. Major viral causes of ALRI and pneumonia in infants and children include respiratory syncytial virus, influenza, adenoviruses, parainfluenza 3, and human metapneumovirus. While viruses are the predominant cause of ALRIs, especially in the young, respiratory bacterial pathogens are most often implicated in childhood deaths from pneumonia (1). The predominant bacterial pathogen is Streptococcus pneumoniae, which dominates across all age groups, but other important pathogens include Haemophilus influenzae, Staphylococcus aureus and, in older children, Mycoplasma pneumoniae (11). Other common causes of severe pneumonia are measles in regions where vaccine uptake is poor, non-typhoid Salmonella species in regions of Africa where malaria is endemic, Klebsiella pneumoniae in malnourished children and neonates, and Pneumocystis jirovecii and Mycobacterium tuberculosis, especially in HIV positive infants and children.
Current studies determining the etiology of pneumonia vary substantially with respect to factors that influence the diagnosis and ascribed microbial etiology. These include case definitions, use of and interpretation of chest x-rays (CXR), peripheral blood white cell counts, and inflammatory markers, depth of investigations, facility type, and patient characteristics. Consequently, studies describe different frequency and types of pathogens associated with pneumonia. The Pneumonia Etiology Research for Child Health (PERCH) project is the largest multisite study (6000 children, 7 African and Asian countries) of childhood pneumonia. It seeks to address the aforementioned limitations by using case-control methodologies and adopting a protocol that has standardized enrollment criteria, specimen collection, laboratory testing, and molecular detection techniques (12).
The Knowledge Gaps
Despite advances in identifying microorganisms using highly sensitive molecular techniques, ascribing causation is problematic. Nucleic acid amplification (NAA) techniques, such as polymerase chain reaction (PCR) assays, identify genetic material, but the implicated microbe may no longer be viable or infectious and their presence may be from a recent, but unrelated respiratory illness. For example, the prevalence of respiratory viruses detected by molecular techniques in asymptomatic children is as high as 42% (13) and strains of adenovirus C may remain latent in mucosal lymphocytes and be shed for months or even years (14).
Even when the same molecular detection techniques for viruses are used, the site of specimen collection influences results. In paired comparisons of concurrently obtained upper and lower airway specimens for respiratory viruses in 75 children, we found significant discordance between nasopharyngeal aspirate and bronchoalveolar lavage (BAL) specimens (manuscript submitted) (15). The discordance was dependent on the virus type and most marked for human rhinovirus and adenoviruses. Additionally, we (16) and others (17) have found that even when investigating viral infections from a single specimen collection site, detection of multiple viral types is not uncommon. This observation compounds the difficulty in determining the primary causative agent and presents new questions about the roles of these viruses in the etiology of the disease.
The ideal samples for determining etiologic agents in bacterial pneumonia are lower airway specimens. It is usually neither necessary nor feasible to obtain either BAL or needle lung aspirate specimens in acute pneumonia. Induced sputum is an alternative only in older children, and as potential respiratory bacterial pathogens commonly colonize the upper airways of healthy children, oropharyngeal contamination can complicate interpretation of culture results. Blood cultures are also infrequently (<10%) positive in children with pneumonia and as PCVs become incorporated into national immunization schedules their sensitivity is likely to be further reduced (18). PCR techniques have only modestly increased the yield of pathogen detection in blood samples (19), while with the exception of M. pneumoniae, serology is impractical in most clinical situations. Thus, it remains a challenge to determine the ideal, yet feasible, specimen for identifying the etiological agent(s) in pneumonia.
Increasingly, viral–viral, viral-bacterial, and bacterial–bacterial interactions in the pathogenesis of respiratory infections are recognized with in vitro and in vivo animal (20) and human studies (21, 22). Thus, although viruses may initiate the respiratory infection, secondary bacterial infection may occur, and simply identifying a virus at presentation (leading to antibiotics being with-held) may not indicate the sole etiology of the child’s acute clinical presentation or determine its long-term outcomes.
The complexity of the microbial contribution is further increased by introducing the world of “-omics” (e.g., metagenomics). While interest in this field is exploding, its use may further complicate ascribing etiology to a single organism. Although analysis of gene expression signatures shows considerable promise for identifying causative pathogens of pneumonia (23), these and other NAA platforms (e.g., microbead arrays, microarray) are unlikely to be made available in the near future to resource-poor countries where the burden of childhood pneumonia is greatest.
Prevention and Contributing Factors
Vaccines, such as pertussis, measles, and more recently Hib and PCVs, have reduced the worldwide incidence of pneumonia (24). However, the benefit from population vaccination programs is not always uniform, as for example in the case of PCV-7, which although having significantly reduced pneumonia rates in target and some older age groups (24), its impact on other populations living in resource-rich nations has been surprisingly limited. Despite achieving high population PCV-7 vaccination rates of ∼90%, the incidence of World Health Organization (WHO)-defined radiographic pneumonia was not reduced in the Indigenous population living in the Northern Territory of Australia (25).
In resource-poor nations, important factors identified for increasing the risk of pneumonia include overcrowding, access to clean water, malnutrition, anemia, young maternal age, low birth weight, and exposure to tobacco smoke and other environmental pollutants. Several of these risk factors also contribute to children in resource-rich nations developing pneumonia.
The Knowledge Gaps
The contribution of asthma or asthma-like illness to pneumonia remains controversial (26). While people with asthma have minor intrinsic abnormalities in their immune responses (27) leading to a predisposition to viral lung infections and occasionally invasive pneumococcal disease, it is also possible that some children with asthma may have been misdiagnosed as pneumonia (26). Further information on the contribution (e.g., misdiagnosis or co-morbidity) of the asthma phenotype to early childhood pneumonia, especially in resource-limited countries, is warranted (26).
Good hygiene practices reduce ALRIs and promotion of safe hygiene is the single most cost-effective means of preventing infectious disease (28). However, how best to make safe hygiene practices a matter of daily routine is yet to be determined (28).
In some settings, such as in Indigenous settings in the US and Australia, a combination of factors underlie why the young children living in remote communities experience a high burden of pneumonia. While housing is very important, housing upgrades can be insufficient to improve health outcomes in children and a broader approach is required (29). Exactly what this entails is yet to be determined, but factors likely to be important are adequate water supply and minimizing indoor air pollution.
Current case definitions for pneumonia vary considerably and are highly setting dependent (18). In WHO-defined pneumonia, cough or breathing difficulties, and age-adjusted tachypnea are sufficient for diagnosing mild-to-moderate pneumonia, but these criteria were designed for health workers with relatively little training. However, the diagnostic thresholds for respiratory rate differ between the WHO, US, and United Kingdom (UK) guidelines (30, 31). Furthermore, even within affluent countries such as the US, the diagnostic criteria, and testing for pneumonia within hospital Emergency Departments varies widely (32).
Community healthcare workers often diagnose pneumonia on history and examination (respiratory rate, dyspnea, auscultatory findings). However, in young children with a cough, chest auscultatory findings, even by doctors (general practitioners), are unreliable with kappa values (0.39, 95% CI 0.26–0.53) (33) below the acceptable clinical range.
While many studies use CXRs as the gold standard (18), there is disagreement over whether a CXR should be an index test. Current USA (31) and UK (34) guidelines on childhood pneumonia do not advocate CXRs outside of hospital settings. Furthermore, their interpretation is subjective often resulting in additional diagnostic variability. Also, CXRs are insensitive when compared to chest computed tomography (CT) scans (35). While chest CT scans will not be used to diagnose pneumonia in the usual clinical setting, the poor sensitivity of CXRs means they too cannot be used as a diagnostic gold standard.
Laboratory tests (e.g., C-reactive protein, peripheral blood white cell count, erythrocyte sedimentation rate) are ancillary and non-diagnostic tests. In adults with community-acquired pneumonia, employing procalcitonin levels to initiate and cease antibiotics might be useful, however, procalcitonin diagnostic thresholds in childhood pneumonia are less defined and their usefulness and safety in guiding management has not been established (18).
The Knowledge Gaps
World Health Organization has published a standardized method to define radiographic pneumonia (based on CXRs) for epidemiological studies and vaccine trials (36). The WHO definition for primary endpoint consolidation WHO-EPC (36) was framed to be more specific for likely bacterial pneumonia than those used for clinical purposes. However, some authors have applied the WHO-EPC definition in the clinical context (24), an approach that we do not recommend (37). In a blinded study, a pediatric pulmonologist’s assessment of radiographic pneumonia in a cohort of children hospitalized with clinical pneumonia, had significantly higher positive predicted value for the presence of auscultatory crackles and elevated peripheral blood white cell counts when compared to WHO-EPC read by a panel standardized to interpret WHO-EPC (37). Others have raised similar concerns, with left lower and right middle lobe consolidation and non-alveolar pneumonia causing the greatest levels of disagreement (37, 38).
A systematic review compared 11 different “gold standards” for identifying bacterial pneumonia and found that diagnostic tests used for pediatric pneumonia have not been validated rigorously (18). Some advocate chest ultrasounds for diagnosing pneumonia (24), but this approach has not been validated. While chest ultrasounds may provide adequate images of some lobes, they will not for others, particularly the right middle lobe. Thus, using another sub-optimal diagnostic tool will only complicate the field further.
The lack of a universally agreed diagnostic gold standard for childhood pneumonia, especially one that can also differentiate between bacterial and non-bacterial pneumonia is a major limitation in clinical research in this area. Vaccine probes have proven useful at a population level, but they under-estimate the burden of disease as no vaccine is 100% efficacious or, in the case of PCVs, protects against all disease causing serotypes. Instead, valid standards useful for various scenarios should be developed. These include standards for clinical, epidemiological, and treatment purposes, such as defining when antibiotics should be used (as opposed to conceptually a purely bacterial or viral-based etiology).
Managing childhood pneumonia relies upon several factors:
a. Child factors
• Demographics (e.g., age, immunization status, household contacts, etc.)
• Severity of pneumonia (e.g., hypoxemia, complications)
• Co-morbidities (e.g., malnutrition, HIV, other immunodeficiencies, malaria, underlying cardiac, pulmonary, neuromuscular, or metabolic disorders)
b. External factors
• Country (health care facilities)
• Setting (urban vs. rural; hospital vs. community)
Pneumonia case management, especially in resource-poor regions, is important (39). These focus on: (a) antimicrobial therapy when appropriate, (b) correcting hypoxemia, (c) fluid and nutritional management, (d) treatment of co-morbidities, and (e) close observation for developing complications. National treatment guidelines exist (31, 34), but there is wide variability in managing pneumonia, even in resource-rich countries (40).
The Knowledge Gaps
Some issues specific to pneumonia management in resource-poor settings were highlighted recently (39). These included difficulties in differentiating clinically between pneumonia and other common serious illnesses in infants and young children living in these regions, such as bronchiolitis and malaria, issues over when to refer for inpatient management, antibiotic choice when HIV, tuberculosis, and Salmonella infections are common, micronutrients use, definition of hypoxemia, and defining and managing treatment failure in the acute setting.
While basic management principles are known, the details of the “how, when and what” remain uncertain. For example, with oxygen; when should it be initiated, what pulse oxygen saturation should be targeted once oxygen supplementation is commenced and how best to deliver oxygen (pure or mixed, high or low flow) is still unknown. Because of the cost implications for resource-poor countries and randomized controlled trial (RCT) evidence that high concentration oxygen therapy may result in adverse outcomes in adults with acute asthma (41), these issues that might seem unimportant, are highly relevant in improving clinical care.
The many RCTs involving antibiotics have so far only focused on short-term outcomes and increasingly shorter courses of antibiotics have been advocated. None however, have focused on the length of wet or productive cough post-treatment. As with oxygen, while this may appear unimportant, the persistence of chronic wet cough (signifying persistence of excessive airway secretions and lower airway infection) is associated with developing bronchiectasis in children (42).
Further, outside of vaccine trials, most RCTs on treating pneumonia in the last two decades were based in resource-poor areas (30) where risk factors, etiology, patient characteristics, and settings differ substantially from resource-rich countries. Meta-analysis of studies have shown discrepancies in results between studies conducted in resource-poor vs. resource-rich settings (43). Those conducted in resource-poor regions have in some cases had significantly more favorable treatment effects than in resource-rich settings (43).
The primary objective of childhood pneumonia management has focused largely on preventing mortality in resource-poor countries and reducing hospitalization rates in resource-rich nations. Here, we propose three tiers for managing pneumonia in children. With the increasing awareness of chronic disease in developing countries (including lung disease) and that a substantial amount of chronic lung disease originates in childhood (42, 44, 45), in an ideal world all tiers should be targeted at clinical practice. The main objectives of each tier and on-going research questions within each of these objectives include:
a. Preventing mortality
Identifying who needs hospitalization
Recognizing who needs oxygen
When to start antibiotics and in whom and for how long?
b. Reducing short-term morbidity
Type and duration of antibiotic courses
Duration of oxygen supplementation and weaning
Identifying and treating co-morbidities, including malnutrition
Preventing and managing complications
c. Promoting return to full and long-term health
Identifying and treating on-going symptoms post-acute episode
Preventing recurrences and long-term sequelae
Consequences of Pneumonia
Simple pneumonia may evolve into complicated pneumonia, defined by developing parapneumonic effusions, empyema, pyopneumothorax, or necrotizing pneumonia. Interestingly, the incidence of complicated pneumonia has increased over the last two decades and has occurred in countries before and after introducing PCVs into the immunization schedule (46), although there are encouraging signs from the UK that the incidence may now be declining after changing from a PCV-7 to PCV-13 schedule. However, it is beyond the scope of this article to discuss complicated pneumonia further.
Few studies have closely followed-up children with pneumonia. In a study of 78 Australian Indigenous children hospitalized with pneumonia and followed for 12-months afterward, 26% had new treatable chronic respiratory symptoms identified (47). Meanwhile, in a New Zealand study, 74% of the 81 children with an adequately performed CXR 10–14 months post-hospitalization for an ALRI had features of on-going respiratory morbidity (wet cough, auscultatory chest crackles, CXR abnormalities) (5).
The alveolar stage of human lung development occurs from 36-weeks gestation and continues for at least 7-years post-natally (48). Hence, early infectious or inflammatory insults in the first few years of life, when postnatal lung development is the most important, are most likely to result in long-term effects. While low birth weight can influence future lung function, there is increasing evidence that early life events, such as pneumonia, are at least equally important determinants of adult lung dysfunction, as shown in human and animal studies (44, 45, 49, 50).
In adult cohort studies, recurrent ALRIs are independent risk factors for subsequent chronic obstructive pulmonary disease (44, 49), although they did not confirm the history of prior childhood pneumonia. There are very few long-term pediatric follow-up studies. One case-control study on bronchiectasis showed that hospitalized pneumonia was a risk factor, particularly when it was recurrent and/or severe (51). An English study of 103 children found that children post (median 5.6-years) hospitalized pneumonia were significantly more likely to have persistent cough or asthma than controls (52). Similarly, a Gambian-based study showed that 68 children hospitalized previously with pneumonia had significantly higher odds (2.8, 95% CI 1.1–7.4) of chronic lung disease at follow-up 12–14 years later (53).
The Knowledge Gap
Many gaps in persistent morbidity and long-term sequelae from pneumonia exist. The concept of the post-bronchiolitis syndrome is appreciated increasingly (54) and in the last decade the WHO has emphasized the origins of adult chronic lung disease from early in life and that potential intervention trials should begin during this critical developmental stage of lung growth and development.
We have highlighted some of the key knowledge gaps in diagnosing and managing childhood pneumonia. Clinical trials are now needed in various settings to address these gaps. We propose a tiered approach and a framework to advance this field so as to reduce the short and long-term burden associated with pneumonia in children.
Anne B. Chang conceptualized the manuscript and wrote the first draft. Keith Grimwood, Mong H. Ooi, and David Perera amended the manuscript.
Conflict of Interest Statement
Anne B. Chang has received funding from GlaxoSmithKline for an investigator driven study on the effects of Synflorix® on airway bacteriology. Keith Grimwood has participated on advisory boards to GlaxoSmithKline on pneumonia and pneumococcal conjugate vaccines. Mong H. Ooi and David Perera have no conflict of interest.
Anne B. Chang is supported by a NHMRC practitioner fellowship (545216) and this work supported by a NHMRC Centre for Research Excellence for lung health in Aboriginal and Torres Strait Islanders grant (1040830).
5. Trenholme AA, Byrnes CA, McBride C, Lennon DR, Chan-Mow F, Vogel AM, et al. Respiratory health outcomes 1 year after admission with severe lower respiratory tract infection. Pediatr Pulmonol (2013) 48:772–9. doi:10.1002/ppul.22661
9. Singleton RJ, Valery PC, Morris P, Byrnes CA, Grimwood K, Redding G, et al. Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol (2013). doi:10.1002/ppul.22763
10. Holman RC, Curns AT, Cheek JE, Singleton RJ, Anderson LJ, Pinner RW. Infectious disease hospitalizations among American Indian and Alaska native infants. Pediatrics (2003) 111:E176–82. doi:10.1542/peds.111.2.e176
11. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics (2004) 113:701–7. doi:10.1542/peds.113.4.701
12. Gilani Z, Kwong YD, Levine OS, Deloria-Knoll M, Scott JA, O’Brien KL, et al. A literature review and survey of childhood pneumonia etiology studies: 2000-2010. Clin Infect Dis (2012) 54(Suppl 2):S102–8. doi:10.1093/cid/cir1053
15. Wurzel D, Marchant JM, Clark JE, Mackay IM, Wang CYT, Sloots TP, et al. Yield of respiratory virus detection in nasopharyngeal aspirate versus broncho-alveolar lavage is dependent on virus type in children with chronic respiratory symptoms. J Clin Virol (in press). doi:10.1016/j.jcv.2013.09.016
16. Chang AB, Clark R, Acworth JP, Petsky HL, Sloots TP. The impact of viral respiratory infection on the severity and recovery from an asthma exacerbation. Pediatr Infect Dis J (2009) 28:290–4. doi:10.1097/INF.0b013e31819067b1
17. Buecher C, Mardy S, Wang W, Duong V, Vong S, Naughtin M, et al. Use of a multiplex PCR/RT-PCR approach to assess the viral causes of influenza-like illnesses in Cambodia during three consecutive dry seasons. J Med Virol (2010) 82:1762–72. doi:10.1002/jmv.21891
18. Lynch T, Bialy L, Kellner JD, Osmond MH, Klassen TP, Durec T, et al. A systematic review on the diagnosis of pediatric bacterial pneumonia: when gold is bronze. PLoS One (2010) 5:e11989. doi:10.1371/journal.pone.0011989
19. Esposito S, Marchese A, Tozzi AE, Rossi GA, Da Dalt L, Bona G, et al. Bacteremic pneumococcal community-acquired pneumonia in children less than 5 years of age in Italy. Pediatr Infect Dis J (2012) 31:705–10. doi:10.1097/INF.0b013e31825384ae
21. Pavia AT. What is the role of respiratory viruses in community-acquired pneumonia?: what is the best therapy for influenza and other viral causes of community-acquired pneumonia? Infect Dis Clin North Am (2013) 27:157–75. doi:10.1016/j.idc.2012.11.007
25. O’Grady KA, Taylor-Thomson DM, Chang AB, Torzillo PJ, Morris PS, Mackenzie GA, et al. Rates of radiologically confirmed pneumonia as defined by the world health organization in Northern Territory indigenous children. Med J Aust (2010) 192:592–5.
29. Bailie RS, Stevens M, McDonald EL. The impact of housing improvement and socio-environmental factors on common childhood illnesses: a cohort study in indigenous Australian communities. J Epidemiol Community Health (2012) 66:821–31. doi:10.1136/jech.2011.134874
31. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis (2011) 53:e25–76. doi:10.1093/cid/cir625
32. Florin TA, French B, Zorc JJ, Alpern ER, Shah SS. Variation in emergency department diagnostic testing and disposition outcomes in pneumonia. Pediatrics (2013) 132:237–44. doi:10.1542/peds.2013-0179
34. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British thoracic society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax (2011) 66:ii1–23. doi:10.1136/thoraxjnl-2011-200598
36. World Health Organization Pneumonia Vaccine Trial Investigators Group. Standardization of Interpretation Chest Radiographs for the Diagnosis of Pneumonia in Children. Geneva: World Health Organization (2001).
37. O’Grady KA, Torzillo PJ, Ruben AR, Taylor-Thomson D, Valery PC, Chang AB. Identification of radiological alveolar pneumonia in children with high rates of hospitalized respiratory infections: comparison of WHO-defined and pediatric pulmonologist diagnosis in the clinical context. Pediatr Pulmonol (2011) 47(4):386–92. doi:10.1002/ppul.21551
38. Ben Shimol S, Dagan R, Givon-Lavi N, Tal A, Aviram M, Bar-Ziv J, et al. Evaluation of the world health organization criteria for chest radiographs for pneumonia diagnosis in children. Eur J Pediatr (2012) 171:369–74. doi:10.1007/s00431-011-1543-1
39. Graham SM, English M, Hazir T, Enarson P, Duke T. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. Bull World Health Organ (2008) 86:349–55. doi:10.2471/BLT.07.048512
40. Rowan-Legg A, Barrowman N, Shenouda N, Koujok K, Le SN. Community-acquired lobar pneumonia in children in the era of universal 7-valent pneumococcal vaccination: a review of clinical presentations and antimicrobial treatment from a Canadian pediatric hospital. BMC Pediatr (2012) 12:133. doi:10.1186/1471-2431-12-133
41. Rodrigo GJ, Rodriquez VM, Peregalli V, Rodrigo C. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest (2003) 124:1312–7. doi:10.1378/chest.124.4.1312
43. Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ (2013) 346:f707. doi:10.1136/bmj.f707
44. Dharmage SC, Erbas B, Jarvis D, Wjst M, Raherison C, Norbäck D, et al. Do childhood respiratory infections continue to influence adult respiratory morbidity? Eur Respir J (2009) 33:237–44. doi:10.1183/09031936.00062907
45. Snibson K, Harding R. Postnatal growth rate, but not mild preterm birth, influences airway structure in adult sheep challenged with house dust mite. Exp Lung Res (2008) 34:69–84. doi:10.1080/01902140701807720
46. Chibuk TK, Robinson JL, Hartfield DS. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with pneumococcal conjugate vaccine (PCV7). Eur J Pediatr (2010) 169:1123–8. doi:10.1007/s00431-010-1195-6
50. Maritz G, Probyn M, De MR, Snibson K, Harding R. Lung parenchyma at maturity is influenced by postnatal growth but not by moderate preterm birth in sheep. Neonatology (2008) 93:28–35. doi:10.1159/000105522
51. Valery PC, Torzillo PJ, Mulholland EK, Boyce NC, Purdie DM, Chang AB. A hospital-based case-control study of bronchiectasis in indigenous children in Central Australia. Pediatr Infect Dis J (2004) 23:902–8. doi:10.1097/01.inf.0000142508.33623.2f
53. Puchalski Ritchie LM, Howie SR, Arenovich T, Cheung YB, Weber M, Moore S, et al. Long-term morbidity from severe pneumonia in early childhood in the Gambia, West Africa: a follow-up study. Int J Tuberc Lung Dis (2009) 13:527–32.
Keywords: pneumonia, acute respiratory infections, diagnosis, treatment, outcomes
Citation: Chang AB, Ooi MH, Perera D and Grimwood K (2013) Improving the diagnosis, management, and outcomes of children with pneumonia: where are the gaps? Front. Pediatr. 1:29. doi: 10.3389/fped.2013.00029
Received: 14 September 2013; Paper pending published: 30 September 2013;
Accepted: 06 October 2013; Published online: 23 October 2013.
Edited by:Michael David Shields, Queen’s University Belfast, Northern Ireland
Reviewed by:Ignacio Tapia, University of Pennsylvania, USA
Mario Barreto, University of Rome La Sapienza, Italy
Michael David Shields, Queen’s University Belfast, Northern Ireland
Copyright: © 2013 Chang, Ooi, Perera and Grimwood. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anne B. Chang, Department of Respiratory Medicine, Royal Children’s Hospital, Herston, QLD 4029, Australia e-mail: firstname.lastname@example.org